Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opsens Inc V.OPS


Primary Symbol: T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

<< Previous
Bullboard Posts
Next >>
Post by bossuon Jul 12, 2022 10:29am
169 Views
Post# 34817836

Woryh noting on the Financial aspect...

Woryh noting on the Financial aspect...From the Q2 financial report:
''
  • Cash and cash equivalents of $30.9-million at Feb. 28, 2022 ($38.6-million at Aug. 31, 2021).
  • Consolidated sales were $8.1-million in Q2 2022 compared with $8.8-million in Q2 2021 due to supply chain disruptions that affected manufacturing and distribution of the company's products, as well as a decrease in hospitals procedure volumes.
  • Net loss was $2.4-million in Q2 2022 compared with a net income of $41,000 in Q2 2021.
  • Excellent xash position and low cash burning rate
  • Stunning deal with Premier Inc 

Probably a small loss in the Q3 but very promissing ''outlook''in the coming months.

Will see what Louis well have  to report next Thursday !

Cannot be but very good news !
<< Previous
Bullboard Posts
Next >>